🔗 Share this article

The initial novel therapies for gonorrhoea in a generation are being hailed as a "major milestone" in the effort against increasingly resistant strains of the bacteria, according to scientists.

A Worldwide Challenge

Cases of gonorrhoea are increasing worldwide, with data suggesting in excess of 82 million new cases each year. Particularly high rates are seen in the African continent and countries within the World Health Organization's designated area, which spans from China and Mongolia to New Zealand. Within England, cases have hit a all-time high, while rates across Europe in 2023 were significantly elevated compared to figures for 2014.

“The clearance of new treatments for gonorrhoea is an critical and opportune advancement in the face of rising global incidence, escalating drug resistance and the very limited therapeutic options at this time.”

Public health authorities are deeply concerned about the rise in drug-resistant strains. The WHO has listed it as a "priority pathogen". A tracking program found that the effectiveness of key first-line drugs like cefixime and ceftriaxone jumped significantly between 2022 and 2024.

Two New Treatment Options Secure Approval

Zoliflodacin, alternatively called a brand name, was authorized by the US FDA in recent days for use against gonorrhoea. This disease can lead to significant complications, including infertility. Researchers hope that focused deployment of this new drug will help hinder the spread of drug resistance.

Another new antibiotic, created by the pharmaceutical company GlaxoSmithKline, was also approved in close succession. This medication, which is also used to treat UTIs, was demonstrated in studies to be successful in treating drug-resistant strains of the gonorrhoea bacteria.

An Innovative Partnership

This new treatment was the result of a new, not-for-profit approach for antibiotic development. The charitable organization GARDP partnered with the drug firm its industry partner to see it through.

“This milestone signifies a major breakthrough in the therapy of multidrug-resistant gonorrhoea, which until now has been outpacing our drug pipeline.”

Research Study Data and Global Access

As per findings released by a prominent scientific publication, zoliflodacin successfully treated over nine in ten of genital gonorrhoea infections. This establishes an similar efficacy with the existing first-line therapy, which involves an injection and a pill. The trial included over 900 volunteers from various regions including the United States, Thailand, South Africa, and European nations.

Through the arrangement of its development partnership, GARDP has the authority to license and sell the drug in a wide range of low-income and middle-income countries.

Medical professionals on the front lines have expressed optimism. Access to a easy-to-administer therapy of this kind is described as a "game-changer" for managing the epidemic. This is considered essential to alleviate the strain of the illness for people and to stop the proliferation of extremely resistant gonorrhoea globally.